Category - Feature

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Feature

Vivos transforming the lives of patients with obstructive sleep apnea

Vivos Therapeutics (NASDAQ:VVOS) is developing and commercializing innovative diagnostic and treatment methods for adult and pediatric patients suffering from sleep-related breathing disorders, including severe...

March 25, 2025

Feature

Future Fields fueling custom protein biomanufacturing with the power of fruit flies

Closely held Future Fields is spearheading the world’s first synthetic biology system with an innovative transgenic bug-based approach—leveraging fruit flies to combine genetic engineering with insect farming to unlock...

March 18, 2025

Feature

Evergen pushing the boundaries of tissue engineering in regenerative medicine

Closely held Evergen, formerly RTI Surgical, is advancing innovative medical solutions across the cardiac, sports and orthopedics, plastic and reconstructive surgery, and neuro-spine clinical segments as the only...

March 4, 2025

Feature

Climb driving transformational therapies in immune-mediated diseases

Climb Bio (NASDAQ:CLYM) is advancing a pipeline of best-in-class, patient-tailored therapeutics to address the unmet needs of complex and clinically-diverse immune-mediated diseases.

February 18, 2025

Feature

MOBILion trailblazing next-gen separation science to reveal what others leave unseen

Closely held MOBILion Systems is redefining analytical characterization through its next-generation separation science platform that is integrated with high-resolution mass spectrometry to achieve unprecedented...

February 4, 2025

Feature

VICO addressing severe neurological diseases at the source with RNA modulating therapies

Closely held VICO Therapeutics is developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe genetic neurological diseases, including Huntington’s disease (HD) and spinocerebellar...

January 21, 2025

Feature

ROMTech advancing postoperative rehabilitation with unparalleled patient outcomes

Closely held ROMTech is combining cutting-edge innovation with advanced telemedicine technology, transforming rehabilitation, diagnostics, facilitating seamless remote patient-physician connections for at-home...

January 14, 2025

Category - Feature

Subscribe